Financhill
Sell
8

TEVA Quote, Financials, Valuation and Earnings

Last price:
$17.00
Seasonality move :
2.83%
Day range:
$17.00 - $17.63
52-week range:
$12.51 - $22.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.16x
P/B ratio:
3.59x
Volume:
10.1M
Avg. volume:
13.7M
1-year change:
30.07%
Market cap:
$19.3B
Revenue:
$16.5B
EPS (TTM):
-$1.45

Analysts' Opinion

  • Consensus Rating
    Teva Pharmaceutical Industries has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $23.79, Teva Pharmaceutical Industries has an estimated upside of 39.92% from its current price of $17.00.
  • Price Target Downside
    According to analysts, the lowest downside price target is $18.07 representing -6.29% downside risk from its current price of $17.00.

Fair Value

  • According to the consensus of 9 analysts, Teva Pharmaceutical Industries has 39.92% upside to fair value with a price target of $23.79 per share.

TEVA vs. S&P 500

  • Over the past 5 trading days, Teva Pharmaceutical Industries has overperformed the S&P 500 by 3.99% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Teva Pharmaceutical Industries does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Teva Pharmaceutical Industries revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Teva Pharmaceutical Industries reported revenues of $4.2B.

Earnings Growth

  • Teva Pharmaceutical Industries has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Teva Pharmaceutical Industries reported earnings per share of -$0.19.
Enterprise value:
34.1B
EV / Invested capital:
1.45x
Price / LTM sales:
1.16x
EV / EBIT:
81.47x
EV / Revenue:
2.06x
PEG ratio (5yr expected):
-0.06x
EV / Free cash flow:
45.53x
Price / Operating cash flow:
25.66x
Enterprise value / EBITDA:
43.89x
Gross Profit (TTM):
$8.1B
Return On Assets:
-3.93%
Net Income Margin (TTM):
-9.91%
Return On Equity:
-23.87%
Return On Invested Capital:
-6.34%
Operating Margin:
21.8%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $14.9B $15.8B $16.5B $4.5B $4.2B
Gross Profit $7B $7.6B $8.1B $2.4B $2.1B
Operating Income $2.7B $3.2B $3.4B $1.3B $922M
EBITDA -$926M $1.6B $777M $994M $261M
Diluted EPS -$2.12 -$0.51 -$1.45 $0.41 -$0.19
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $13B $12.6B $12.1B $12.5B $12.6B
Total Assets $50.6B $47.7B $44B $43.5B $39.3B
Current Liabilities $13.2B $11B $11.5B $12.2B $12.8B
Total Liabilities $39.6B $36.4B $35.4B $35.4B $33.6B
Total Equity $11.1B $11.2B $8.6B $8.1B $5.7B
Total Debt $25.9B $23B $21.2B $19.8B $17.8B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $1.6B $1.4B $1.2B $1.2B $575M
Cash From Investing $656M $968M $792M $301M $202M
Cash From Financing -$1.5B -$1.9B -$1.8B -$576M -$674M
Free Cash Flow $1B $842M $749M $1.1B $446M
TEVA
Sector
Market Cap
$19.3B
$44.2M
Price % of 52-Week High
74.56%
48.19%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
30.07%
-35.43%
Beta (5-Year)
0.711
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $16.67
200-day SMA
Sell
Level $17.81
Bollinger Bands (100)
Sell
Level 16.56 - 20.54
Chaikin Money Flow
Sell
Level -855.2M
20-day SMA
Sell
Level $18.00
Relative Strength Index (RSI14)
Sell
Level 37.53
ADX Line
Sell
Level 41.26
Williams %R
Neutral
Level -58.9286
50-day SMA
Sell
Level $19.56
MACD (12, 26)
Sell
Level -0.97
25-day Aroon Oscillator
Sell
Level -52
On Balance Volume
Neutral
Level 12.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.2956)
Sell
CA Score (Annual)
Level (-1.9209)
Buy
Beneish M-Score (Annual)
Level (-2.9979)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.1579)
Buy
Piotroski F Score (Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Stock Forecast FAQ

In the current month, TEVA has received 6 Buy ratings 3 Hold ratings, and 0 Sell ratings. The TEVA average analyst price target in the past 3 months is $23.79.

  • Where Will Teva Pharmaceutical Industries Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Teva Pharmaceutical Industries share price will rise to $23.79 per share over the next 12 months.

  • What Do Analysts Say About Teva Pharmaceutical Industries?

    Analysts are divided on their view about Teva Pharmaceutical Industries share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Teva Pharmaceutical Industries is a Sell and believe this share price will drop from its current level to $18.07.

  • What Is Teva Pharmaceutical Industries's Price Target?

    The price target for Teva Pharmaceutical Industries over the next 1-year time period is forecast to be $23.79 according to 9 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is TEVA A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Teva Pharmaceutical Industries is a Buy. 6 of 9 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of TEVA?

    You can purchase shares of Teva Pharmaceutical Industries via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Teva Pharmaceutical Industries shares.

  • What Is The Teva Pharmaceutical Industries Share Price Today?

    Teva Pharmaceutical Industries was last trading at $17.00 per share. This represents the most recent stock quote for Teva Pharmaceutical Industries. Yesterday, Teva Pharmaceutical Industries closed at $17.00 per share.

  • How To Buy Teva Pharmaceutical Industries Stock Online?

    In order to purchase Teva Pharmaceutical Industries stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is SoFi Worth?
What Is SoFi Worth?

Since SoFi’s CEO began snapping up shares of the student…

Is CVX a Buy, Sell or Hold?
Is CVX a Buy, Sell or Hold?

Energy giant Chevron Corporation (NYSE:CVX) has long been a pure-play…

What Will NVIDIA Stock Be Worth in 2030?
What Will NVIDIA Stock Be Worth in 2030?

NVIDIA (NASDAQ:NVDA) has been by far one of the best…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
22
FRPT alert for Feb 21

Freshpet [FRPT] is down 18.55% over the past day.

Sell
18
SUPN alert for Feb 21

Supernus Pharmaceuticals [SUPN] is up 3.19% over the past day.

Buy
85
FTAI alert for Feb 21

FTAI Aviation [FTAI] is up 14.41% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock